Developing new MRI techniques using healthy volunteers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on acquiring magnetic resonance (MR) data from healthy volunteers to develop and validate new MR protocols and techniques. The aim is to enhance the speed, quality, and range of measurements possible with MR imaging. Volunteers will undergo non-invasive scanning procedures, with strict safety protocols in place to ensure their well-being. The data collected will support methodological research into MR imaging and processing techniques, contributing to advancements in clinical research applications.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Healthy volunteers will be recruited by email from within departments at UCL and UCLH
* male or female
* Aged 18 and above

Exclusion Criteria:

* volunteers with pacemakers or other implanted devices, or with other metallic foreign bodies, will be excluded.
* Women who may be pregnant
* any participants who cannot give informed consent (including anyone who may not adequately understand the verbal explanations or written information given in English)

Where it's running

• University College London
  London, United Kingdom Recruiting

Study contacts

• Study coordinator: Neela Ramchurn
• Email: n.ramchurn1@nhs.net

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Monitoring and Early Detection of Treatable Inherited Retinal Disease in Children and Adolescents

  This study tests AI tools to spot and track inherited retinal diseases caused by RPE65 and RPGR mutations using widefield eye images in kids and teens.

  Recruiting University College, London · Boston, Massachusetts and 2 other locations · NCT07901907

• Oral Progestin Tablets With Radiotherapy vs. Standard Radiotherapy and Chemotherapy in High-Risk NSMP Endometrial Cancer

  This trial tests whether adding oral progestin tablets after radiotherapy is as effective as the standard radiotherapy plus chemotherapy for high-risk NSMP endometrial cancer, hoping to reduce side effects and improve quality of life.

  Recruiting at 12 sites Phase 3 University College, London · Bath and 11 other locations · NCT07831902

• MIGHTY: CAR T cells targeting B7-H3 for pediatric, teen, and young adult sarcoma

  This Phase 1 trial tests autologous hBRCA84D CAR T cells in kids, teens, and young adults (1–24) with relapsed or refractory RMS, ES, or DSRCT to see if the therapy is feasible and safe.

  Recruiting at 2 sites Phase 1 University College, London · London and 1 other locations · NCT07751380

• Lower-dose ARPI therapy for metastatic prostate cancer

  This trial tests whether using half the usual dose of ARPI therapy can work as well as a full dose for men with metastatic prostate cancer who are also receiving standard hormone therapy.

  Recruiting at 4 sites Phase 3 University College, London · Huddersfield and 3 other locations · NCT07751133

• Treatments for sustained improvement in symptomatic Alzheimer’s disease (18 months)

  This trial tests whether adding atomoxetine or metformin to standard care helps people with Alzheimer’s disease or related dementia see lasting improvements over 18 months.

  Recruiting at 2 sites Phase 3 University College, London · Cambridge and 1 other locations · NCT07724132

• Impact of an accessory pudendal artery on erection recovery after nerve-sparing prostate surgery

  This study checks if preserving an extra artery (the accessory pudendal artery) during robotic prostate removal helps men regain erections after nerve-sparing surgery.

  Recruiting University College, London · London · NCT07597798

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.